To investigate the mechanism by which TRIM6 regulates sensitivity to ICB therapy in gastric cancer, we analyzed tumor-infiltrating lymphocytes via flow cytometry using two mouse tumor models under anti-PD-L1 treatment: MTC (with Trim6 depletion), and MFC (with Trim6 overexpression). The gene discussed is TRIM6; the disease is medullary thyroid gland carcinoma.